Pharmanutra Statistics

Total Valuation

Pharmanutra has a market cap or net worth of EUR 524.59 million. The enterprise value is 524.67 million.

Market Cap	524.59M
Enterprise Value	524.67M

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharmanutra has 9.61 million shares outstanding. The number of shares has decreased by -0.07% in one year.

Current Share Class	n/a
Shares Outstanding	9.61M
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	+1.59%
Owned by Insiders (%)	10.73%
Owned by Institutions (%)	15.80%
Float	4.27M

Valuation Ratios

The trailing PE ratio is 32.39 and the forward PE ratio is 26.45.

PE Ratio	32.39
Forward PE	26.45
PS Ratio	4.66
PB Ratio	8.92
P/TBV Ratio	14.85
P/FCF Ratio	27.01
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.45, with an EV/FCF ratio of 27.01.

EV / Earnings	32.25
EV / Sales	4.64
EV / EBITDA	17.45
EV / EBIT	19.84
EV / FCF	27.01

Financial Position

The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.42.

Current Ratio	2.26
Quick Ratio	1.76
Debt / Equity	0.42
Debt / EBITDA	0.81
Debt / FCF	1.26
Interest Coverage	24.21

Financial Efficiency

Return on equity (ROE) is 29.54% and return on invested capital (ROIC) is 20.72%.

Return on Equity (ROE)	29.54%
Return on Assets (ROA)	14.83%
Return on Capital (ROIC)	20.72%
Revenue Per Employee	950,630
Profits Per Employee	136,731
Employee Count	105
Asset Turnover	1.02
Inventory Turnover	7.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.11% in the last 52 weeks. The beta is 0.31, so Pharmanutra's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	-4.11%
50-Day Moving Average	55.20
200-Day Moving Average	52.67
Relative Strength Index (RSI)	49.84
Average Volume (20 Days)	4,626

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmanutra had revenue of EUR 113.13 million and earned 16.27 million in profits. Earnings per share was 1.69.

Revenue	113.13M
Gross Profit	57.09M
Operating Income	26.44M
Pretax Income	26.36M
Net Income	16.27M
EBITDA	29.55M
EBIT	26.44M
Earnings Per Share (EPS)	1.69

Full Income Statement

Balance Sheet

The company has 24.40 million in cash and 24.48 million in debt, giving a net cash position of -82,000 or -0.01 per share.

Cash & Cash Equivalents	24.40M
Total Debt	24.48M
Net Cash	-82,000
Net Cash Per Share	-0.01
Equity (Book Value)	58.90M
Book Value Per Share	6.12
Working Capital	35.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 22.87 million and capital expenditures -3.45 million, giving a free cash flow of 19.42 million.

Operating Cash Flow	22.87M
Capital Expenditures	-3.45M
Free Cash Flow	19.42M
FCF Per Share	2.02

Full Cash Flow Statement

Margins

Gross margin is 50.47%, with operating and profit margins of 23.37% and 14.38%.

Gross Margin	50.47%
Operating Margin	23.37%
Pretax Margin	23.30%
Profit Margin	14.38%
EBITDA Margin	26.12%
EBIT Margin	23.37%
FCF Margin	17.17%

Dividends & Yields

This stock pays an annual dividend of 0.85, which amounts to a dividend yield of 1.56%.

Dividend Per Share	0.85
Dividend Yield	1.56%
Dividend Growth (YoY)	6.25%
Years of Dividend Growth	3
Payout Ratio	50.22%
Buyback Yield	0.07%
Shareholder Yield	1.62%
Earnings Yield	3.09%
FCF Yield	3.70%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pharmanutra has an Altman Z-Score of 7.79.

Altman Z-Score	7.79
Piotroski F-Score	n/a